Chandler Park, MD, MSc, FACP

Articles

Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC

March 8th 2024

David A. Braun, MD, PhD, shares his takeaways from the network meta-analysis on lenvatinib plus pembrolizumab in advanced RCC, and Martin H. Voss, MD, discusses outcomes with cabozantinib following frontline lenvatinib plus pembrolizumab.

LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis

March 8th 2024

Chandler H. Park, MD, discusses the LEAP study investigating lenvatinib plus pembrolizumab in patients with renal cell carcinoma with brain metastasis.

Dr Park on the Sequencing of Treatment Options in Metastatic Urothelial Cancer

March 6th 2024

Chandler H. Park, MD, FACP, discusses the implications of the phase 2 TROPHY-U-01 trial in metastatic urothelial carcinoma.

Recent Subgroup Analyses from the CLEAR study in Advanced RCC

March 1st 2024

Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.

CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC

March 1st 2024

Laurence Albigès, MD, PhD, reviews recently presented data from CheckMate 67T, which is assessing subcutaneous vs intravenous nivolumab in patients with previously treated RCC.

Long-Term Follow-Up from CheckMate 214 in Advanced RCC

February 23rd 2024

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.

First-Line Treatments for Advanced Clear Cell RCC

February 23rd 2024

A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.

Dr Park on the Rationale for the TROPHY-U-01 Trial in Urothelial Carcinoma

February 22nd 2024

Chandler H. Park, MD, FACP, discusses the rationale for evaluating sacituzumab govitecan plus pembrolizumab in metastatic urothelial carcinoma.

Dr Park on the Use of Sacituzumab Govitecan Plus Pembrolizumab in Urothelial Carcinoma

February 20th 2024

Chandler H. Park, MD, FACP, discusses the use of sacituzumab govitecan plus pembrolizumab in patients with metastatic urothelial carcinoma.

Dr Park on Navigating of Later-line Treatment Options in Metastatic Urothelial Carcinoma

May 9th 2023

Chandler Park, MD, MSc, FACP, discusses the navigation and selection of later-line treatments for patients with metastatic urothelial carcinoma.

Dr. Park on the Increasing Use of Biomarker Testing and Radiotheranostics in Prostate Cancer

March 6th 2023

Chandler Park, MD, MSc, FACP, discusses how the emerging field of radiotheranostics and increasing utilization of biomarker testing will improve the treatment of patients with metastatic hormone-sensitive prostate cancer.